# Human serum influences functional plasticity and transcriptomic landscape of γδ T cells in vitro

**Authors:** Lorraine Pinot, Zhibek Zhumadilova, Aylin Saßor, Sagar, José Villacorta Hidalgo

PMC · DOI: 10.3389/fimmu.2026.1722590 · Frontiers in Immunology · 2026-02-10

## TL;DR

This study shows that growing γδ T cells in serum-free conditions improves their quality and function for potential cancer therapies.

## Contribution

The study demonstrates that serum-free culture enhances γδ T cell expansion and function while maintaining diversity and reducing variability.

## Key findings

- Serum-free culture supports robust γδ T cell expansion with higher purity and an activated phenotype.
- Serum-free expanded cells show comparable or enhanced cytotoxicity and cytokine production.
- TCR repertoire diversity is preserved without clonal skewing in both serum-free and serum-containing conditions.

## Abstract

γδ T cells are emerging as a promising platform for adoptive cell therapy due to their ability to recognize tumors independently of MHC and their minimal risk of causing graft-versus-host disease. While serum-supplemented media have traditionally been used for T cell expansion, they can present limitations including xenogeneic contaminants and batch variability. These issues can compromise T cell phenotype, function, and clinical reproducibility. In this study, we evaluated the impact of human serum on the expansion, phenotype, function, and transcriptomic landscape of Vγ9Vδ2 γδ T cells cultured with zoledronate and cytokines under serum-free versus serum-containing conditions. We evaluated cytotoxicity against triple-negative breast cancer cell lines, activation and checkpoint marker expression, and cytokine secretion. Single-cell RNA and TCR sequencing revealed consistent differentiation trajectories across donors in both conditions and gene expression dynamics during a two-week expansion period. Our results show that serum-free culture supports robust γδ T cell expansion with higher purity and an activated phenotype marked by increased activation markers and reduced checkpoint receptor expression. Serum-free expanded cells displayed comparable or enhanced cytotoxicity and cytokine production, especially IFN-γ. TCR repertoire diversity was preserved without clonal skewing in both conditions. Furthermore, re-exposure to serum late in culture had minimal influence on γδ T cell functionality. These findings demonstrate the feasibility and advantages of serum-free expansion protocols for Vγ9Vδ2 γδ T cells, offering improved consistency, safety, and therapeutic potential.

## Linked entities

- **Proteins:** IFNG (interferon gamma)
- **Chemicals:** zoledronate (PubChem CID 68740)
- **Diseases:** triple-negative breast cancer (MONDO:0005494)

## Full-text entities

- **Genes:** ISG15 (ISG15 ubiquitin like modifier) [NCBI Gene 9636] {aka G1P2, IFI15, IMD38, IP17, UCRP, hUCRP}, GNLY (granulysin) [NCBI Gene 10578] {aka D2S69E, LAG-2, LAG2, NKG5, TLA519}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, MX2 (MX dynamin like GTPase 2) [NCBI Gene 4600] {aka MXB}, HAVCR2 (hepatitis A virus cellular receptor 2) [NCBI Gene 84868] {aka CD366, HAVcr-2, KIM-3, SPTCL, TIM3, TIMD-3}, TRDV1 (T cell receptor delta variable 1) [NCBI Gene 28518] {aka hDV101S1}, APP (amyloid beta precursor protein) [NCBI Gene 351] {aka AAA, ABETA, ABPP, AD1, APPI, CTFgamma}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, PTPRC (protein tyrosine phosphatase receptor type C) [NCBI Gene 5788] {aka B220, CD45, CD45R, GP180, IMD105, L-CA}, MKI67 (marker of proliferation Ki-67) [NCBI Gene 4288] {aka KIA, MIB-, MIB-1, PPP1R105}, TCF7 (transcription factor 7) [NCBI Gene 6932] {aka TCF-1}, FDPS (farnesyl diphosphate synthase) [NCBI Gene 2224] {aka FPPS, FPS, POROK9}, TRBV20OR9-2 (T cell receptor beta variable 20/OR9-2 (non-functional)) [NCBI Gene 6962] {aka CDR3, TCRBV20S2, TCRBV2O, TCRBV2S2O}, LAMP1 (lysosome associated membrane protein 1) [NCBI Gene 3916] {aka CD107a, LAMPA, LGP120}, STAT1 (signal transducer and activator of transcription 1) [NCBI Gene 6772] {aka CANDF7, IMD31A, IMD31B, IMD31C, ISGF-3, STAT91}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, TRG (T cell receptor gamma locus) [NCBI Gene 6965] {aka TCRG, TRG@}, CD14 (CD14 molecule) [NCBI Gene 929], GZMK (granzyme K) [NCBI Gene 3003] {aka GrK, TRYP2}, TIGIT (T cell immunoreceptor with Ig and ITIM domains) [NCBI Gene 201633] {aka VSIG9, VSTM3, WUCAM}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, CSF2 (colony stimulating factor 2) [NCBI Gene 1437] {aka CSF, GMCSF}, CD69 (CD69 molecule) [NCBI Gene 969] {aka AIM, BL-AC/P26, CLEC2C, EA1, GP32/28, MLR-3}, PRF1 (perforin 1) [NCBI Gene 5551] {aka HPLH2, P1, PFP}, KLRK1 (killer cell lectin like receptor K1) [NCBI Gene 22914] {aka CD314, D12S2489E, KLR, NKG2-D, NKG2D}, GZMB (granzyme B) [NCBI Gene 3002] {aka C11, CCPI, CGL-1, CGL1, CSP-B, CSPB}, IL7R (interleukin 7 receptor) [NCBI Gene 3575] {aka CD127, CDW127, IL-7R-alpha, IL-7Ralpha, IL7RA, IL7Ralpha}, IFNG (interferon gamma) [NCBI Gene 3458] {aka IFG, IFI, IMD69}, IFNA1 (interferon alpha 1) [NCBI Gene 3439] {aka IFL, IFN, IFN-ALPHA, IFN-alphaD, IFNA13, IFNA@}, S1PR1 (sphingosine-1-phosphate receptor 1) [NCBI Gene 1901] {aka CD363, CHEDG1, D1S3362, ECGF1, EDG-1, EDG1}, CD19 (CD19 molecule) [NCBI Gene 930] {aka B4, CVID3}, MX1 (MX dynamin like GTPase 1) [NCBI Gene 4599] {aka IFI-78K, IFI78, MX, MxA, lncMX1-215}, CD27 (CD27 molecule) [NCBI Gene 939] {aka S152, S152. LPFS2, T14, TNFRSF7, Tp55}, SELL (selectin L) [NCBI Gene 6402] {aka CD62L, LAM1, LECAM1, LEU8, LNHR, LSEL}, IL2 (interleukin 2) [NCBI Gene 3558] {aka IL-2, TCGF, lymphokine}
- **Diseases:** Tumor (MESH:D009369), Graft versus Host Disease (MESH:D006086), cytotoxic (MESH:D064420), TNBC (MESH:D064726), breast cancer (MESH:D001943)
- **Chemicals:** 7-AAD (MESH:C025942), T (MESH:D014316), saline (MESH:D012965), Brefeldin A (MESH:D020126), mevalonate (MESH:D008798), phosphate (MESH:D010710), Bafilomycin A1 (MESH:C040929), biotin (MESH:D001710), essential amino acids (MESH:D000601), E (MESH:D004540), Zoledronate (MESH:D000077211), 5microM (-), IPP (MESH:C004809), PEB (MESH:C038328), Tween 20 (MESH:D011136), PBS (MESH:D007854), bisphosphonate (MESH:D004164), 4',6-diamidino-2-phenylindole (MESH:C007293), CO2 (MESH:D002245), glutamine (MESH:D005973)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** MDA-MB-468 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0419), MDA-MB-157 — Homo sapiens (Human), Breast carcinoma, Cancer cell line (CVCL_0618), MDA-MB-231 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0062)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12929466/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12929466/full.md

## References

40 references — full list in the complete paper: https://tomesphere.com/paper/PMC12929466/full.md

---
Source: https://tomesphere.com/paper/PMC12929466